UNICYCIVE THERAPEUTICS, INC. Other Income and Expense
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Other Income and Expense of $8.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. nonoperating income (expense) for the quarter ending 2026-06-30 was $8.42M, a 1531.40% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. nonoperating income (expense) for the quarter ending 2026-03-31 was -$4.39M, a 151.24% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. nonoperating income (expense) for the quarter ending 2025-12-31 was -$7.44M.
- UNICYCIVE THERAPEUTICS, INC. nonoperating income (expense) for the quarter ending 2025-09-30 was $1.33M, a 38.24% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. nonoperating income (expense) for fiscal 2025 was $2.96M.
- UNICYCIVE THERAPEUTICS, INC. nonoperating income (expense) for fiscal 2024 was -$4.61M.
- UNICYCIVE THERAPEUTICS, INC. nonoperating income (expense) for fiscal 2023 was -$9.77M.
- UNICYCIVE THERAPEUTICS, INC. nonoperating income (expense) for fiscal 2022 was -$6.00K.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 3 month as first filed | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 6 month as first filed | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8.42M 10-Q · filed 2026-08-12 | $4.03M 10-Q · filed 2026-08-12 | -$3.41M derived: sum of 3 quarters · filed 2026-08-12 | -$2.08M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$4.39M 10-Q · filed 2026-05-12 | -$11.83M derived: sum of 2 quarters · filed 2026-05-12 | -$10.50M derived: sum of 3 quarters · filed 2026-05-12 | -$9.98M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | -$7.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$6.11M derived: sum of 2 quarters · filed 2026-03-30 | -$5.60M derived: sum of 3 quarters · filed 2026-08-12 | $2.96M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $1.33M 10-Q · filed 2025-11-12 | $1.85M derived: sum of 2 quarters · filed 2026-08-12 | $10.41M 10-Q · filed 2025-11-12 | -$1.86M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $516.00K 10-Q · filed 2026-08-12 | $9.09M 10-Q · filed 2026-08-12 | -$3.19M derived: sum of 3 quarters · filed 2026-08-12 | -$1.03M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $8.56M 10-Q · filed 2026-05-12 | -$3.71M derived: sum of 2 quarters · filed 2026-05-12 | -$1.55M derived: sum of 3 quarters · filed 2026-05-12 | $15.71M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$12.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$10.11M derived: sum of 2 quarters · filed 2026-03-30 | $7.15M derived: sum of 3 quarters · filed 2026-03-30 | -$4.61M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $2.15M 10-Q · filed 2025-11-12 | $19.41M derived: sum of 2 quarters · filed 2025-11-12 | $7.65M 10-Q · filed 2025-11-12 | $6.17M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $17.26M 10-Q · filed 2025-08-14 | $5.50M 10-Q · filed 2025-08-14 | $4.01M derived: sum of 3 quarters · filed 2025-08-14 | $5.62M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$11.76M 10-Q · filed 2025-05-14 | -$13.24M derived: sum of 2 quarters · filed 2025-05-14 | -$11.64M derived: sum of 3 quarters · filed 2025-05-14 | -$11.15M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $120.00K derived: sum of 2 quarters · filed 2025-03-31 | $604.00K derived: sum of 3 quarters · filed 2025-03-31 | -$9.77M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $1.60M 10-Q · filed 2024-11-13 | $2.09M derived: sum of 2 quarters · filed 2024-11-13 | -$8.29M 10-Q · filed 2024-11-13 | -$8.29M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $484.00K 10-Q · filed 2024-08-14 | $282.00K 10-Q · filed 2023-08-14 | -$9.89M 10-Q · filed 2024-08-14 | -$10.09M 10-Q · filed 2023-08-14 | -$9.89M derived: sum of 3 quarters · filed 2024-08-14 | -$9.90M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$10.38M 10-Q · filed 2023-05-16 | -$10.38M derived: sum of 2 quarters · filed 2023-05-16 | -$10.38M derived: sum of 3 quarters · filed 2023-05-16 | |||
| 2022-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$6.00K derived: sum of 2 quarters · filed 2023-03-31 | -$6.00K 10-K · filed 2023-03-31 | |||
| 2022-09-30 | -$3.00K 10-Q · filed 2022-11-14 | -$3.00K 10-Q · filed 2022-11-14 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$486.00K derived: sum of 2 quarters · filed 2023-03-31 | -$807.00K derived: sum of 3 quarters · filed 2023-03-31 | -$1.04M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | -$486.00K 10-Q · filed 2022-11-14 | -$807.00K derived: sum of 2 quarters · filed 2022-11-14 | -$1.04M 10-Q · filed 2022-11-14 | -$1.20M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | -$321.00K 10-Q · filed 2022-08-15 | -$554.00K 10-Q · filed 2022-08-15 | -$717.00K derived: sum of 3 quarters · filed 2022-08-15 | -$793.00K derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | -$233.00K 10-Q · filed 2022-05-12 | -$396.00K derived: sum of 2 quarters · filed 2022-05-12 | -$472.00K derived: sum of 3 quarters · filed 2022-05-12 | -$474.00K derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$239.00K derived: sum of 2 quarters · filed 2022-03-31 | -$241.00K derived: sum of 3 quarters · filed 2022-03-31 | -$244.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | -$76.00K 10-Q · filed 2021-11-12 | -$78.00K derived: sum of 2 quarters · filed 2021-11-12 | -$81.00K 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$2.00K 10-Q · filed 2021-08-16 | -$4.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |